Profound Medical Unveils AI-Powered BPH Module at RSNA and SUO Meetings
Profound Medical Corp. unveiled its AI-powered TULSA-AI Volume Reduction module for treating benign prostatic hyperplasia (BPH) at the RSNA and SUO conferences. The company also presented new clinical data on its TULSA-PRO procedure for prostate cancer, emphasizing its precision and efficiency. The events included live demonstrations and presentations, showcasing the technology's impact on prostate disease treatment. This news was originally published by Profound Medical via GlobeNewswire on November 28, 2025.
Profound Medical Corp. showcased its latest innovations at two major medical conferences, the Radiological Society of North America (RSNA) in Chicago and the Society for Urologic Oncology (SUO) in Phoenix. At RSNA, the company launched its AI-powered TULSA-AI Volume Reduction module, designed to optimize treatment for patients with benign prostatic hyperplasia (BPH). Profound Medical also presented new clinical data on its TULSA-PRO procedure for prostate cancer at both RSNA and SUO, highlighting the technology’s versatility, precision, and efficiency in treating prostate diseases. The events featured live demonstrations, special presentations, and updates on the clinical impact of the TULSA Procedure. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Profound Medical Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9593573-en) on November 28, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
